XML 22 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Total Varex Equity
Total Varex Equity
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Noncontrolling Interests
Balance at beginning of period at Oct. 02, 2020 $ 465.8   $ 451.7   $ 0.4 $ 434.4   $ 0.8 $ 16.1   $ 14.1
Shares outstanding, beginning of period (in shares) at Oct. 02, 2020         39,100,000            
Increase (Decrease) in Stockholders' Equity                      
Net income 17.9   17.4           17.4   0.5
Common stock issued upon vesting of restricted shares (in shares)         200,000            
Shares withheld on vesting of restricted stock (1.5)   (1.5)     (1.5)          
Shares withheld on vesting of restricted stock (in shares)         (100,000)            
Common stock issued under employee stock purchase plan 2.8   2.8     2.8          
Common stock issued under employee stock purchase plan (in shares)         200,000            
Share-based compensation 13.9   13.9     13.9          
Unrealized and realized loss (gain) on forward contracts 0.0                    
Unrealized loss (gain) on change in fair value of available-for-sale securities 0.0                    
Unrealized loss (gain) on defined benefit obligations, net of tax (0.1)   (0.1)         (0.1)      
Foreign currency translation adjustments (0.7)   (0.7)         (0.7)      
Other (1.6)   (0.2)     (0.2)         (1.4)
Balance at ending of period at Oct. 01, 2021 496.5   483.3   $ 0.4 449.4   0.0 33.5   13.2
Shares outstanding, end of period (in shares) at Oct. 01, 2021         39,400,000            
Increase (Decrease) in Stockholders' Equity                      
Net income 30.8   30.3           30.3   0.5
Exercise of stock options 3.8   3.8     3.8          
Exercise of stock options (in shares)         100,000            
Common stock issued upon vesting of restricted shares (in shares)         400,000            
Shares withheld on vesting of restricted stock (2.8)   (2.8)     (2.8)          
Shares withheld on vesting of restricted stock (in shares)         (100,000)            
Common stock issued under employee stock purchase plan 4.9   4.9     4.9          
Common stock issued under employee stock purchase plan (in shares)         300,000            
Share-based compensation 14.0   14.0     14.0          
Unrealized and realized loss (gain) on forward contracts (0.6)   (0.6)         (0.6)      
Unrealized loss (gain) on change in fair value of available-for-sale securities (0.1)   (0.1)         (0.1)      
Unrealized loss (gain) on defined benefit obligations, net of tax 1.4   1.4         1.4      
Foreign currency translation adjustments (0.6)   (0.6)         (0.6)      
Other (0.6)   (0.2)     (0.2)         (0.4)
Balance at ending of period at Sep. 30, 2022 $ 546.7 $ (28.5) 533.4 $ (28.5) $ 0.4 469.1 $ (34.6) 0.1 63.8 $ 6.1 13.3
Shares outstanding, end of period (in shares) at Sep. 30, 2022 40,085,126       40,100,000            
Increase (Decrease) in Stockholders' Equity                      
Accounting Standards Update [Extensible List] Accounting Standards Update 2020-06                    
Net income $ 48.7   48.2           48.2   0.5
Exercise of stock options $ 0.2   0.2     0.2          
Exercise of stock options (in shares) 13,000                    
Common stock issued upon vesting of restricted shares (in shares)         200,000            
Shares withheld on vesting of restricted stock $ (1.4)   (1.4)     (1.4)          
Shares withheld on vesting of restricted stock (in shares)         (100,000)            
Common stock issued under employee stock purchase plan 3.9   3.9     3.9          
Common stock issued under employee stock purchase plan (in shares)         300,000            
Share-based compensation 13.5   13.5     13.5          
Unrealized and realized loss (gain) on forward contracts 0.1   0.1         0.1      
Unrealized loss (gain) on change in fair value of available-for-sale securities 0.1   0.1         0.1      
Unrealized loss (gain) on defined benefit obligations, net of tax (1.0)   (1.0)         (1.0)      
Foreign currency translation adjustments (0.5)   (0.5)         (0.5)      
Other (0.8)   (0.3)     (0.3)         (0.5)
Balance at ending of period at Sep. 29, 2023 $ 581.0   $ 567.7   $ 0.4 $ 450.4   $ (1.2) $ 118.1   $ 13.3
Shares outstanding, end of period (in shares) at Sep. 29, 2023 40,529,573       40,500,000